Sepragen in the News
Sepragen along with SUNY, Albany win NIIMBL grant for “Novel Bioreactor for hematopoietic cell expansion.
Sepragen wins NIIMBL award for “Rapid Continuous Production of Room Temperature Stable mRNA vaccines.
Sepragen ships two, 125 LPM Custom Chromatography Systems with inline integrated Buffer Blending Capability for Covid-19 vaccine production in 14 weeks to enable ramp from 40M doses to 200M doses/ month.
Sepragen partners with I&L Biosystems to distribute it’s products in Europe.